Diagnostic Specialty Antibodies Global Market Report 2024

The diagnostic specialty antibodies market size has grown strongly in recent years. It will grow from $28.33 billion in 2023 to $29.97 billion in 2024 at a compound annual growth rate (CAGR) of 5.8%. The growth observed in the historical period can be ascribed to progress in biotechnology, the advent of personalized medicine, enhanced understanding of diseases, advancements in immunoassay and diagnostic techniques, and the ascent of companion diagnostics.

The diagnostic specialty antibodies market size is expected to see strong growth in the next few years. It will grow to $37.75 billion in 2028 at a compound annual growth rate (CAGR) of 5.9%. The anticipated growth in the forecast period can be ascribed to the proliferation of disease biomarkers, the swift adoption of point-of-care testing, the emergence of infectious diseases, advancements in biosimilar and generic development, and the integration of artificial intelligence and machine learning. Major trends expected in the forecast period encompass technological progress in assay development, the incorporation of nanotechnology, improved specificity and selectivity, integration with wearable devices, and the ongoing miniaturization of assays.

The anticipated growth of the diagnostic specialty antibodies market is expected to be fueled by the expanding patient pool for HIV diagnoses. This refers to the increasing number of individuals being diagnosed with HIV (Human Immunodeficiency Virus). The growing patient pool creates opportunities for manufacturers to develop and supply specialized antibody-based diagnostic products for HIV testing, facilitating the detection of specific biomarkers associated with the virus and aiding in the early detection and monitoring of HIV infection. For instance, as of July 2022, The Joint United Nations Programme on HIV/AIDS (UNAIDS) reported a 1.6% increase in the global population living with HIV, from 37.8 million in 2020 to 38.4 million in 2021. Additionally, around 1.5 million new HIV infections were reported in 2021. Therefore, the growing patient pool of HIV diagnoses is a driving force behind the growth of the diagnostic specialty antibodies market.

The increasing incidence of cancer is expected to contribute to the growth of the diagnostic specialty antibodies market. Cancer, characterized by the uncontrolled division and growth of abnormal cells, prompts the use of diagnostic specialty antibodies to identify specific cancer markers and assist in the diagnosis and monitoring of the disease. According to the American Cancer Society, there were an estimated 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in the United States in 2021, marking an increase from the 1.8 million new cancer cases and 606,520 cancer deaths reported in 2020. Hence, the rising incidence of cancer is a significant driver for the diagnostic specialty antibodies market.


Major companies focusing on the introduction of novel products and solutions to consolidate their market position. A case in point is Creative Diagnostics, a US-based company in the biotechnology industry, which, in January 2023, launched 1,000 new targets. This includes carrier-free formulations and conjugated antibodies, expanding the company's monoclonal antibody capabilities and product offerings on a global scale. The newly introduced monoclonal antibodies are designed to be versatile and high-performing tools applicable in various scenarios, such as ELISA (enzyme-linked immunoassay) detection methods. Their single-epitope recognition ensures improved specificity. These antibodies, having undergone rigorous validation, are suitable for applications such as Western blotting (WB), flow cytometry (FC), immunohistochemistry (IHC), immunocytochemistry (ICC), immunofluorescence (IF), and immunoprecipitation (IP).

Major players in the diagnostic specialty antibodies market are concentrating on the development of innovative assays, specifically antibody assays, for diagnosing rare bleeding disorders and gaining a competitive advantage. An antibody assay is a laboratory technique used to identify and measure the presence and concentration of antibodies in a biological sample. For instance, in May 2023, Versiti, a US-based nonprofit organization, launched the Anti-von Willebrand Factor (VWF) Antibody Assay. This groundbreaking assay aids clinicians in identifying patients suspected of having acquired von Willebrand Disease (aVWD) by detecting both inhibitory and non-inhibitory antibodies binding to VWF, providing additional pathways for anti-VWF antibody detection.

In October 2022, Sebia, a France-based specialty diagnostic company, made an undisclosed acquisition of Zeus Scientific Inc. Through this strategic move, Sebia aims to enhance its capability to deliver high-value solutions to customers and patients while strengthening its foothold and operations in the United States. Zeus Scientific Inc. is a US-based in vitro diagnostic (IVD) company with expertise in antibody tests for autoimmune and infectious diseases.

Major companies operating in the diagnostic specialty antibodies market report are F. Hoffmann-La Roche AG, Sanofi SA, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Boehringer Ingelheim International GmbH, Merck KGaA, Becton Dickinson and Company, Regeneron Pharmaceuticals Inc., Agilent Technologies Inc., Sartorius AG, Bio-Rad Laboratories Inc., Quest Diagnostics Inc., STEMCELL Technologies Inc., Abcam PLC, Telix Pharmaceuticals Limited, Aytu BioScience Inc., Enzo Life Sciences Inc., Rockland Immunochemicals Inc., Santa Cruz Biotechnology Inc., Creative Diagnostics, Novus Biologicals LLC, Confo Therapeutics SA, Precirix NV, Creative Biolabs Inc., Polymun Scientific Immunbiologische Forschung GmbH.

North America was the largest region in the diagnostic specialty antibodies market in 2023. Asia-Pacific is expected to be the fastest-growing region in the diagnostic specialty antibodies market report during the forecast period. The regions covered in the diagnostic specialty antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diagnostic specialty antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of diagnostic specialty antibodies encompass monoclonal antibodies, polyclonal antibodies, and recombinant polyclonal antibodies. Monoclonal antibodies, derived from a single clone of immune cells, yield a uniform population of antibodies that target a specific antigen. These antibodies are employed across various applications, including diagnostics for hepatitis, tuberculosis, dengue, oncology, human immunodeficiency virus (HIV), infectious diseases, and more. Diagnostic laboratories and hospitals serve as key end users utilizing these antibodies.

The diagnostic specialty antibodies research report is one of a series of new reports that provides diagnostic specialty antibodies market statistics, including the diagnostic specialty antibodies industry's global market size, regional shares, competitors with a diagnostic specialty antibodies market share, detailed diagnostic specialty antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the diagnostic specialty antibodies industry. This diagnostic specialty antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The diagnostic specialty antibodies market consists of sales of chimeric antibodies, single-chain antibodies, and bispecific antibodies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.